抗肿瘤药物紫杉醇的不良反应的临床分析
|
摘要
目的:分析和探讨紫杉醇在抗肿瘤应用中的不良反应及临床用药效果。方法:选取70例于2016年12月至2017年12月在我院治疗的肿瘤患者,对其使用紫杉醇药物进行治疗,1个月之后,统计患者发生不良反应的种类以及数量及不良反应发生概率。结果:患者使用抗肿瘤药物紫杉醇出现的不良反应类型分别为骨髓抑制、过敏反应、消化系统、手足麻木以及肝脏损伤,不良反应发生率分别为5.71%、14.29%、2.86%、4.29%和7.14%。结论:紫杉醇在治疗肿瘤的过程中,虽不良反应发生率较低,但也要充分考虑可能出现的不良反应,给予必要的预防及治疗。
Objective:To analyze and discuss the adverse reactions of paclitaxel in antineoplastic application and its clinical efficacy. Methods: 70 cases of tumor treated in our hospital from December 2016 to December 2017 were treated with paclitaxel. A month later, the type, number and probability of adverse reactions were counted. Results: The types of adverse reactions of paclitaxel were bone marrow suppression, allergic reaction, digestive system, numbness of hands and feet, and liver injury. The incidence of adverse reactions were 5.71%, 14.29%, 2.86%, 4.29% and 7.14%, respectively. Conclusion:Although the incidence of adverse reactions of paclitaxel in the treatment of tumors is low, it is necessary to take full account of the possible adverse reactions and give necessary prevention and treatment.
Objective:To analyze and discuss the adverse reactions of paclitaxel in antineoplastic application and its clinical efficacy. Methods: 70 cases of tumor treated in our hospital from December 2016 to December 2017 were treated with paclitaxel. A month later, the type, number and probability of adverse reactions were counted. Results: The types of adverse reactions of paclitaxel were bone marrow suppression, allergic reaction, digestive system, numbness of hands and feet, and liver injury. The incidence of adverse reactions were 5.71%, 14.29%, 2.86%, 4.29% and 7.14%, respectively. Conclusion:Although the incidence of adverse reactions of paclitaxel in the treatment of tumors is low, it is necessary to take full account of the possible adverse reactions and give necessary prevention and treatment.
引文
[1]周琳.抗肿瘤药物不良反应临床分析[J].世界最新医学信息文摘(电子版),2017.
[2]Meng Z,Lv Q,Lu J,et al.Prodrug Strategies for Paclitaxel[J].International Journal of Molecular Sciences,2016,17(5):796.
[3]齐瑞芳,石瑞丽,吕军,等.姜黄素联合紫杉醇在体内外可协同降低乳腺癌MDA-MB-231细胞迁移能力并降低MMP9表达[J].中药药理与临床,2016,32(1):83-85.
[4]王丽娜,张崇建,李连方,等.三阴性乳腺癌表柔比星和环磷酰胺联合紫杉醇周疗新辅助化疗临床观察[J].中华肿瘤防治杂志,2015,22(3):211-215.
[5]Chan B M,Garcia A A.Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer:American Society of Clinical Oncology Clinical Practice Guideline[J].Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology,2014,25(1):18-20.
[6]孙燕,周际昌.临床肿瘤内科手册[M].4版.北京:人民卫生出版社,2003:106-113.
[7]王宝强.紫杉醇联合顺铂同步放化疗治疗局部晚期非小细胞肺癌的临床疗效及安全性评价[J].中国临床药理学杂志,2015,31(8):603-605.
[8]徐晚成.抗癌药物紫杉醇的作用机理及机制[J].滨州医学院学报,2017,40(4):294-297.
[9]刘先芳,梁敬钰,孙建博.紫杉醇:具有里程碑意义的天然抗癌药物[J].世界科学技术-中医药现代化,2017(06):67-75.
[10]李运景.紫杉醇注射液致严重不良反应分析[J].中国现代药物应用,2007,1(6):3-5.
[11]丁有奕,黄渚,王延红.紫杉醇治疗肺癌48例不良反应分析[J].海南医学,2007,18(7):74-75.
[12]谢艾维.紫杉醇的不良反应及其合理应用[J].中国药物经济学,2015,10(1):34-36.
[13]顾海娟,郭小红,朱冬梅,等.卵巢癌患者代谢酶基因多态性与紫杉醇血药浓度及不良反应的相关性[J].中华实用诊断与治疗杂志,2012,26(12):1185-1187.
[14]胡远强,张永波,王华,等.多西他赛联合卡铂与紫杉醇联合顺铂治疗晚期卵巢癌的疗效和安全性比较[J].中国药房,2016,27(24):3353-3356.
[15]夏晓冬.紫杉醇不良反应分析[J].白求恩医学杂志,2011,09(2):141-142.
[16]邹春华,黄涛金,谢勇久,等.奥沙利铂或替吉奥联合紫杉醇治疗进展期胃癌的临床疗效及安全性评价[J].中国临床药理学杂志,2015,31(8):609-611.
[17]叶冬梅,韦海明,兰顺,等.紫杉醇和多烯紫杉醇致肝损害的实验研究[J].时珍国医国药,2011,22(1):182-184.
[18]卢晨欣,孙警辉,伍春莲.白藜芦醇与紫杉醇联合用药对人喉癌Hep-2细胞凋亡机制的研究[J].中国中药杂志,2016,41(3):476-483.
[19]Manju S,Sharma C P,Sreenivasan K.Targeted coadministration of sparingly soluble paclitaxel and curcumin into cancer cells by surface engineered magnetic nanoparticles[J].Journal of Materials Chemistry,2011,21(39):15708.
[20]蒲新霖.紫杉醇和姜黄素在肿瘤治疗中的联合应用[J].西南军医,2017(2):161-164.
[21]刘平,魏子白,于俊岩,等.奈达铂或顺铂联合紫杉醇同步放化疗治疗中晚期宫颈癌的临床疗效观察[J].中华临床医师杂志(电子版),2015,9(10):77-81.
[2]Meng Z,Lv Q,Lu J,et al.Prodrug Strategies for Paclitaxel[J].International Journal of Molecular Sciences,2016,17(5):796.
[3]齐瑞芳,石瑞丽,吕军,等.姜黄素联合紫杉醇在体内外可协同降低乳腺癌MDA-MB-231细胞迁移能力并降低MMP9表达[J].中药药理与临床,2016,32(1):83-85.
[4]王丽娜,张崇建,李连方,等.三阴性乳腺癌表柔比星和环磷酰胺联合紫杉醇周疗新辅助化疗临床观察[J].中华肿瘤防治杂志,2015,22(3):211-215.
[5]Chan B M,Garcia A A.Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer:American Society of Clinical Oncology Clinical Practice Guideline[J].Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology,2014,25(1):18-20.
[6]孙燕,周际昌.临床肿瘤内科手册[M].4版.北京:人民卫生出版社,2003:106-113.
[7]王宝强.紫杉醇联合顺铂同步放化疗治疗局部晚期非小细胞肺癌的临床疗效及安全性评价[J].中国临床药理学杂志,2015,31(8):603-605.
[8]徐晚成.抗癌药物紫杉醇的作用机理及机制[J].滨州医学院学报,2017,40(4):294-297.
[9]刘先芳,梁敬钰,孙建博.紫杉醇:具有里程碑意义的天然抗癌药物[J].世界科学技术-中医药现代化,2017(06):67-75.
[10]李运景.紫杉醇注射液致严重不良反应分析[J].中国现代药物应用,2007,1(6):3-5.
[11]丁有奕,黄渚,王延红.紫杉醇治疗肺癌48例不良反应分析[J].海南医学,2007,18(7):74-75.
[12]谢艾维.紫杉醇的不良反应及其合理应用[J].中国药物经济学,2015,10(1):34-36.
[13]顾海娟,郭小红,朱冬梅,等.卵巢癌患者代谢酶基因多态性与紫杉醇血药浓度及不良反应的相关性[J].中华实用诊断与治疗杂志,2012,26(12):1185-1187.
[14]胡远强,张永波,王华,等.多西他赛联合卡铂与紫杉醇联合顺铂治疗晚期卵巢癌的疗效和安全性比较[J].中国药房,2016,27(24):3353-3356.
[15]夏晓冬.紫杉醇不良反应分析[J].白求恩医学杂志,2011,09(2):141-142.
[16]邹春华,黄涛金,谢勇久,等.奥沙利铂或替吉奥联合紫杉醇治疗进展期胃癌的临床疗效及安全性评价[J].中国临床药理学杂志,2015,31(8):609-611.
[17]叶冬梅,韦海明,兰顺,等.紫杉醇和多烯紫杉醇致肝损害的实验研究[J].时珍国医国药,2011,22(1):182-184.
[18]卢晨欣,孙警辉,伍春莲.白藜芦醇与紫杉醇联合用药对人喉癌Hep-2细胞凋亡机制的研究[J].中国中药杂志,2016,41(3):476-483.
[19]Manju S,Sharma C P,Sreenivasan K.Targeted coadministration of sparingly soluble paclitaxel and curcumin into cancer cells by surface engineered magnetic nanoparticles[J].Journal of Materials Chemistry,2011,21(39):15708.
[20]蒲新霖.紫杉醇和姜黄素在肿瘤治疗中的联合应用[J].西南军医,2017(2):161-164.
[21]刘平,魏子白,于俊岩,等.奈达铂或顺铂联合紫杉醇同步放化疗治疗中晚期宫颈癌的临床疗效观察[J].中华临床医师杂志(电子版),2015,9(10):77-81.